Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

No abstract is available for this paper.

• Publication year

  2025

• Venue

  bioRxiv

• Publication date

  2025-11-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/2025.11.07.686998
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Gutless Helper-Dependent and First-Generation HAdV5 Vectors Have Similar Mechanical Properties and Common Transduction Mechanisms

  2024cited by this paper
• Clinical Application of Adenovirus (AdV): A Comprehensive Review

  2024cited by this paper
• Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease

  2024cited by this paper
• DARPin-fused T cell engager for adenovirus-mediated cancer therapy

  2024cited by this paper
• Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies

  2024cited by this paper
• Structural and Biochemical Requirements for Secretory Component Interactions with Dimeric IgA.

  2024cited by this paper
• Dendritic cell targeting in lymph nodes with engineered modular adapters improves HAdV5 and HC-HAdV5 tumor vaccination by co-secretion of IL-2v and IL-21

  2024cited by this paper
• Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors

  2024cited by this paper
• Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

  2023cited by this paper
• Organ-on-a-chip models for development of cancer immunotherapies

  2023cited by this paper
• IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

  2023cited by this paper
• Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains

  2023cited by this paper
• The emerging role of neutrophil extracellular traps in cancer: from lab to ward

  2023cited by this paper
• Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate

  2023influential reference
• Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo.

  2023cited by this paper
• Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA

  2023cited by this paper
• Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model

  2022influential reference
• FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment

  2022cited by this paper
• The role of neutrophil extracellular traps in cancer progression, metastasis and therapy

  2022cited by this paper
• Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

  2022cited by this paper
• CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

  2022cited by this paper
• Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

  2022cited by this paper
• A role for microfluidic systems in precision medicine

  2022cited by this paper
• Perfusion in Organ-on-Chip Models and Its Applicability to the Replication of Spermatogenesis In Vitro

  2022cited by this paper
• Neutrophil phenotypes and functions in cancer: A consensus statement

  2022cited by this paper
• IgA Complexes Induce Neutrophil Extracellular Trap Formation More Potently Than IgG Complexes

  2022cited by this paper
• Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

  2021cited by this paper
• Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

  2021cited by this paper
• The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.

  2021cited by this paper
• Neutrophil Extracellular Traps (NETs) in Cancer Invasion, Evasion and Metastasis

  2021cited by this paper
• Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

  2021cited by this paper
• Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

  2021cited by this paper
• Neutrophil Extracellular Traps in Cancer.

  2021cited by this paper
• Neutrophils in cancer: heterogeneous and multifaceted

  2021cited by this paper
• A Hybrid In Silico and Tumor-on-a-Chip Approach to Model Targeted Protein Behavior in 3D Microenvironments

  2021cited by this paper
• The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody

  2021influential reference
• The Role of Macrophages in Cancer Development and Therapy

  2021cited by this paper
• Efficient production of recombinant Secretory IgA against Clostridium difficile toxins in CHO-K1 cells.

  2021cited by this paper
• Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy

  2021cited by this paper
• iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy

  2021cited by this paper
• IgA transcytosis and antigen recognition govern ovarian cancer immunity

  2021cited by this paper
• Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies

  2020cited by this paper
• Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis

  2020cited by this paper
• Tumor microenvironment complexity and therapeutic implications at a glance

  2020cited by this paper
• High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy

  2020cited by this paper
• Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies?

  2020cited by this paper
• IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47–SIRPα Checkpoint Inhibition

  2019influential reference
• Unravelling Receptor and RGD Motif Dependence of Retargeted Adenoviral Vectors using Advanced Tumor Model Systems

  2019cited by this paper
• Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

  2019influential reference
• Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice

  2019cited by this paper
• Re-education of macrophages as a therapeutic strategy in cancer.

  2019cited by this paper
• Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG

  2019cited by this paper
• ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

  2018influential reference
• Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

  2018influential reference
• Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control

  2018influential reference
• Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer

  2017cited by this paper
• Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy

  2017cited by this paper
• A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

  2016cited by this paper
• An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

  2016cited by this paper
• Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

  2016influential reference
• Site-specific biotinylation of purified proteins using BirA.

  2015cited by this paper
• Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

  2015cited by this paper
• IgA as therapeutic antibody.

  2015cited by this paper
• Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells

  2015cited by this paper
• Macrophages are critical effectors of antibody therapies for cancer

  2015cited by this paper
• Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells

  2015cited by this paper
• The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer

  2014cited by this paper
• IgA Enhances NETosis and Release of Neutrophil Extracellular Traps by Polymorphonuclear Cells via Fcα Receptor I

  2014cited by this paper
• Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters

  2013cited by this paper
• Fiji: an open-source platform for biological-image analysis

  2012cited by this paper
• Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition

  2012cited by this paper
• Structure and function relationships in IgA

  2011cited by this paper
• Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing

  2011cited by this paper
• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

  2010cited by this paper
• Epidermal growth factor receptor modulates the tumorigenic potential of melanoma.

  2009cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor1

  2007cited by this paper
• In search of the elusive mouse macrophage Fc-alpha receptor.

  2006cited by this paper
• Stable antibody expression at therapeutic levels using the 2A peptide

  2005cited by this paper
• Improvement in adenoviral gene transfer efficiency after preincubation at +37 degrees C in vitro and in vivo.

  2002cited by this paper
• Structural requirements for incorporation of J chain into human IgM and IgA.

  2000cited by this paper
• Function of immunoglobulin A in immunity

  2000cited by this paper
• High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

  1999influential reference
• Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18).

  1999cited by this paper
• Benign ethnic neutropenia: what is a normal absolute neutrophil count?

  1999cited by this paper
• High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.

  1998cited by this paper

• No citing papers are available for this paper.